Timur Ivannikov
Stock Analyst at Cantor Fitzgerald
(2.26)
# 2,712
Out of 5,124 analysts
10
Total ratings
50%
Success rate
12.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Timur Ivannikov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Reiterates: Overweight | $8 | $2.02 | +296.04% | 1 | Jun 27, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $28 → $25 | $27.75 | -9.91% | 1 | May 14, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Overweight | $47 | $13.09 | +259.05% | 1 | May 14, 2025 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $5 | $3.10 | +61.29% | 2 | Mar 7, 2023 | |
| ANAB AnaptysBio | Downgrades: Market Perform | n/a | $48.48 | - | 1 | Jan 6, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $22 | $3.51 | +526.78% | 1 | Jul 8, 2022 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $112 → $114 | $25.12 | +353.82% | 1 | Mar 1, 2022 | |
| CBIO Crescent Biopharma | Downgrades: Market Perform | n/a | $11.86 | - | 2 | Nov 15, 2021 |
ProQR Therapeutics
Jun 27, 2025
Reiterates: Overweight
Price Target: $8
Current: $2.02
Upside: +296.04%
Pharvaris
May 14, 2025
Maintains: Overweight
Price Target: $28 → $25
Current: $27.75
Upside: -9.91%
Astria Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $47
Current: $13.09
Upside: +259.05%
Gossamer Bio
Mar 7, 2023
Downgrades: Market Perform
Price Target: $5
Current: $3.10
Upside: +61.29%
AnaptysBio
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $48.48
Upside: -
Rocket Pharmaceuticals
Jul 8, 2022
Initiates: Outperform
Price Target: $22
Current: $3.51
Upside: +526.78%
Apellis Pharmaceuticals
Mar 1, 2022
Maintains: Strong Buy
Price Target: $112 → $114
Current: $25.12
Upside: +353.82%
Crescent Biopharma
Nov 15, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $11.86
Upside: -